Janssen Pharmaceutica NV has described 4-amino-6-oxo-pyridazine derivatives acting as NLRP3 inflammasome inhibitors reported to be useful for the treatment of cancer, asthma and metabolic, autoimmune, liver, renal, cardiovascular and inflammatory disorders, among other disorders.
Mindset Pharma Inc. has patented indole derivatives acting as 5-HT2A receptor agonists reported to be useful for the treatment of neurological disorders and psychosis, among other disorders.
Guangzhou Henovcom Bioscience Co. Ltd. has identified new imidazole TGF-β receptor type-1 (TGFBR1; ALK5; SKR4; TβR-I) inhibitors reported to be useful for the treatment of cancer, hepatic fibrosis, inflammation, osteoporosis, Alzheimer's disease, idiopathic pulmonary fibrosis, diabetic nephropathy and renal disorders, among other disorders.
Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has described new serine/threonine-protein kinase PLK4 (STK18) inhibitors reported to be useful for the treatment of cancer.
Levena Biopharma Co. Ltd. and Sorrento Therapeutics Inc. have synthesized antibody-drug conjugates consisting of auristatin analogues covalently linked to monoclonal antibody targeting B-cell maturation protein (BCMA) through a linker.
Les Laboratoires Servier SAS has divulged new glucagon-like peptide (GLP-1) receptor agonists reported to be useful for the treatment of obesity and diabetes.
First Health Pharmaceuticals BV has presented oxadiazole derivatives acting as DEAD box RNA helicase (DDX) inhibitors reported to be useful for the treatment of cancer.
The Centro Nacional de Investigaciones Oncológicas Carlos III (CNIO) has identified new imidazo[1,2-a]pyrazines acting as serine/threonine-protein kinase haspin (GSG2) inhibitors reported to be useful for the treatment of cancer.
Enanta Pharmaceuticals Inc. has presented heterocyclic compounds reported to be useful for the treatment of respiratory syncytial virus (RSV) and metapneumovirus (MPV) infections.
RSS